The largest community of pharma leaders

Celcuity Announces Appointment of Eric Lindquist as Chief Business Officer

MINNEAPOLIS–()–Celcuity Inc. (Nasdaq: CELC), a functional cellular analysis company that is discovering new cancer subtypes and developing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, today announced that Eric Lindquist joined the company as its Chief Business Officer.

“We are very excited to have Eric join our team and lead Celcuity’s efforts to establish collaborations with pharmaceutical companies and to foster relationships with oncology thought leaders. Eric’s nearly two decades of experience in the companion diagnostic industry brings critical expertise to Celcuity,” said Chairman and Chief Executive Officer, Brian Sullivan. “During his tenure at several leading diagnostic companies, he developed companion diagnostic partnerships with nearly every major pharmaceutical company.”

Prior to joining Celcuity, Mr. Lindquist was the Global Vice President of Oncology and Rare Disease for Natera, Inc. a leading genetic testing diagnostics company. He was responsible for launching their oncology diagnostic product, Signatera, to the pharmaceutical industry and executed more than 30 Signatera related agreements within the first year of its launch. Eric previously served as the Global Vice President of Customer and Companion Diagnostics at Asuragen, a molecular testing company, and as Director, Business Development and Alliances for Companion Diagnostics, at Roche Diagnostics. Early in his career, he was a sales specialist for molecular and companion diagnostics at Abbott Laboratories and a business area leader at Johnson & Johnson’s Veridex division, where he managed co-development partnerships with pharmaceutical and diagnostic companies.

About Celcuity
Celcuity Inc. is a cellular analysis company that is discovering new cancer sub-types and developing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. Celcuity’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular activity driving a patient’s cancer and the targeted therapy that can best treat that patient’s disease. Celcuity is headquartered in Minneapolis, MN. Further information about Celcuity can be found at www.celcuity.com.

Read More

Recent Articles

AVROBIO to Present at Two Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene...

Global Neurofibromatosis Treatment Drugs Market to Surpass US$ 21,223.7 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE--(BUSINESS WIRE)-- #NeurofibromatosisTreatment--The Asia Pacific is expected to witness significant growth...

FDA Approves Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the US Food...

Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced today initiatives to bring attention to...

Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Receives ADLT Status for Envisia Genomic...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.